Description
mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.
Cyan = gene · Slate = variant · Green = drug · Click variant to filter table
Variants (13)
| CIViC ID | Name | HGVS | Type(s) |
|---|---|---|---|
| 610 | A2034V ALA2034VAL | NC_000001.10:g.11187796G>A,ENST00000361445.4:c.6101C>T | missense_variant |
| 543 | C1483Y CYS1483TYR | NC_000001.10:g.11217230C>T,ENST00000361445.4:c.4448G>A,NM_004958.3:c.4448G>A,NP_004949.1:p.Cys1483Tyr | missense_variant |
| 544 | E1799K GLU1799LYS,RS863225264 | NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys,NC_000001.10:g.11190804C>T,ENST00000361445.4:c.5395G>A | missense_variant |
| 572 | E2014K | NM_004958.4:c.6040G>A,NC_000001.10:g.11187857C>T,NP_004949.1:p.Glu2014Lys | missense_variant |
| 4427 | E2419K | ||
| 470 | F2108L PHE2108LEU | NC_000001.10:g.11187094G>T,ENST00000361445.4:c.6324C>A | missense_variant |
| 283 | H1968Y HIS1968TYR | ENST00000361445.4:c.5902C>T,NC_000001.10:g.11188519G>A,NM_004958.3:c.5902C>T,NP_004949.1:p.His1968Tyr | missense_variant,gain_of_function_variant |
| 609 | M2327I MET2327ILE | NC_000001.10:g.11177096C>A,ENST00000361445.4:c.6981G>T | missense_variant |
| 277 | Mutation | protein_altering_variant | |
| 284 | P2213S PRO2213SER | NC_000001.10:g.11184580G>A,ENST00000361445.4:c.6637C>T,NM_004958.3:c.6637C>T,NP_004949.1:p.Pro2213Ser | missense_variant,gain_of_function_variant |
| 3439 | R2152C | ||
| 542 | S2215Y SER2215TYR | NC_000001.10:g.11184573G>T,ENST00000361445.4:c.6644C>A,NM_004958.3:c.6644C>A,NP_004949.1:p.Ser2215Tyr | missense_variant |
| 2712 | T1977K |